Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC has released an overview of the hospital and out-patient reimbursement system in Turkey

01 Oct 2019

Turkey is an interesting and complex market for medical technologies.

A country with a large population and advanced health care service provides on one end, and complex, rigid reimbursement system, complicated by the macro-economic conditions. 

There is only one aspect of market access in Turkey, which is the creation of the Healthcare Implementation Communique (SUT) code for a novel procedure and medical device, as well as a change of the price over time.

A new service must be introduced in one of the annexes of the SUT in order to be reimbursed. There are no transparent processes of the introduction of new services into Annexes of SUT. Also, the system generally lacks the revision of the national reimbursement prices for procedures and devices.

DRG system exists in Turkey, but it is not used for case-by-case reimbursement, and mostly used for benchmarking purposes.

The seminar discusses key stakeholders, money flow, specifics of financing of public and university hospitals, reimbursement in hospital and ambulatory settings, innovation funding, details of the reimbursement application process and the role of health technology assessment. 

Learn more and request a quote here: